Member of the Norwegian Academy of Science and Letters Medicine
Anders Waage mainly investigates Internal medicine, Multiple myeloma, Endocrinology, Surgery and Tumor necrosis factor alpha. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Immunology. In his study, Fatal outcome and Shock is strongly linked to Meningitis, which falls under the umbrella field of Immunology.
His work deals with themes such as Hematology, Cancer research and Bone marrow, which intersect with Multiple myeloma. His Endocrinology research integrates issues from Cell culture and Receptor, Osteoclast. His Surgery research includes themes of Lenalidomide and Oncology.
Anders Waage focuses on Multiple myeloma, Internal medicine, Cancer research, Oncology and Immunology. His studies deal with areas such as Molecular biology, Bone disease and Bone marrow as well as Multiple myeloma. The study incorporates disciplines such as Endocrinology and Surgery in addition to Internal medicine.
His biological study spans a wide range of topics, including Cell culture, Growth factor, Cytokine and Hepatocyte growth factor. His Oncology research is multidisciplinary, incorporating perspectives in Carfilzomib and Clinical trial. His study in the fields of Interleukin 6 and Interleukin under the domain of Immunology overlaps with other disciplines such as Meningococcal disease.
His main research concerns Multiple myeloma, Internal medicine, Oncology, Lenalidomide and Cancer research. His research on Multiple myeloma focuses in particular on Bortezomib. Dexamethasone, Autologous stem-cell transplantation, Thalidomide, Maintenance therapy and Transplantation are the subjects of his Internal medicine studies.
His research in Oncology intersects with topics in Newly diagnosed, Carfilzomib, Staging system and Minimal residual disease. His Cancer research research incorporates elements of Receptor, Myeloma cell, Treatment targets and Bone marrow. His Immunology research incorporates themes from Osteoclast and Review article.
His primary areas of study are Internal medicine, Multiple myeloma, Maintenance therapy, Transplantation and Regimen. His works in Lenalidomide, Clinical endpoint, Autologous stem-cell transplantation and Progression-free survival are all subjects of inquiry into Internal medicine. Multiple myeloma and Mechanism are two areas of study in which he engages in interdisciplinary research.
His Transplantation research is multidisciplinary, incorporating elements of Bortezomib, Ixazomib and Performance status. His Regimen research is multidisciplinary, relying on both Clinical trial and Thalidomide. Anders Waage interconnects Interleukin 6, Immunology, Bioinformatics and RANKL in the investigation of issues within Bone disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome.
A Waage;P Brandtzaeg;A Halstensen;P Kierulf.
Journal of Experimental Medicine (1989)
Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease.
A. Waage;A. Halstensen;T. Espevik.
The Lancet (1987)
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma
Bhairavi Swaminathan;Guðmar Thorleifsson;Magnus Jöud;Mina Ali.
Nature Communications (2015)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson.
Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response.
A Waage;A Halstensen;R Shalaby;P Brandtzaeg.
Journal of Experimental Medicine (1989)
Inflammatory Response After Open Heart Surgery: Release of Heat-Shock Protein 70 and Signaling Through Toll-Like Receptor-4
Brit Dybdahl;Alexander Wahba;Egil Lien;Trude H. Flo.
Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivo
M.R. Shalaby;A. Waage;L. Aarden;T. Espevik.
Clinical Immunology and Immunopathology (1989)
Tumor necrosis factor, interleukin-1, and interleukin-6 in normal human pregnancy
Sissel Linda Opsjøn;Neville C. Wathen;Solveig Tingulstad;Gro Wiedswang.
American Journal of Obstetrics and Gynecology (1993)
Thalidomide for treatment of multiple myeloma: 10 years later
Antonio Palumbo;Thierry Facon;Pieter Sonneveld;Joan Bladè.
Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice.
Anders Waage;Terje Espevik.
Journal of Experimental Medicine (1988)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: